Drugs / E. coli CD-expressing genetically modified neural stem cells
E. coli CD-expressing genetically modified neural stem cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02015819 | Oct 2014 → Oct 2017 | adult glioblastoma, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma +2 | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01172964 | Aug 2010 → Feb 2015 | adult glioblastoma, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma +2 | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E. coli CD-expressing genetically modified neural stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02015819 ↗ |
| Modality | Cell therapy | “genetically-modified neural stem cells” NCT01172964 ↗ |
| Route | Other | “Injected at the time of the surgery to resect the tumor” NCT01172964 ↗ |